SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hurst Stephen L

(Last)

(First)

(Middle)

C/O MIND MEDICINE (MINDMED), INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK

10007

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2022

3. Issuer Name and Ticker or Trading Symbol
Mind Medicine (MindMed) Inc. [ MNMD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Subordinate Voting Shares	100	D
Subordinate Voting Shares	39,000,000	I	By Savant Addiction Medicine, LLC⁽¹⁾
Subordinate Voting Shares	1,722,678	I	By Sunray Asset Management⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽³⁾	09/01/2026	Subordinate Voting Shares	26,285	2.91⁽⁴⁾	D
Directors' Deferred Share Units	⁽⁵⁾	⁽⁵⁾	Subordinate Voting Shares	22,375	⁽⁵⁾	D

Explanation of Responses:

1. These shares are owned by Savant Addiction Medicine, LLC ("Savant Addiction"). The Reporting Person is the managing member of Savant Addiction. The Reporting Person disclaims beneficial ownership of the shares owned by Savant Addiction except to the extent of his pecuniary interest therein.

2. These shares are owned by Sunray Asset Management, Inc. ("Sunray"). The Reporting Person is the Managing Director of Sunray. The Reporting Person disclaims beneficial ownership of the shares owned by Sunray except to the extent of his pecuniary interest therein.

3. The shares underlying the option shall vest and become exercisable in 12 equal monthly installments beginning on March 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date.

4. The option grant has an exercise price of $3.70 Canadian Dollars. This represents the exercise price in United States Dollars.

5. Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective as of April 16, 2021. The DDSUs vest in equal monthly installments over 12 months beginning on March 27, 2021. The DDSUs acquired are to be settled in cash upon the termination of the Reporting Persons' directorship (with each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted will expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (as defined in the Plan).

Remarks:

Exhibit List - Exhibit 24- Power of Attorney

	/s/ Robert Barrow, Attorney-in-Fact	01/10/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.